ARTG Entry
AGOMELATINE
ARTG entry for AGOMELATINE (agomelatine), ARTG 318688 — Product Information, dosage form, registration history. Compiled by arcimedes.
- Sponsor: Southern Cross Pharma
- Active ingredient: agomelatine
- Therapeutic area: Psychiatry
I appreciate the information provided, but
I must inform you that the source document contains only ARTG registration details and does not include sufficient information to complete a comprehensive Brand Dossier as specified.
The document confirms AGOMELATINE SANDOZ, AGOMELATINE ANS, and AGOMELATINE LUPIN are agomelatine 25 mg film-coated tablets registered on the ARTG, first listed on 2020-06-26 . However, the source does not contain information about: — What agomelatine is (mechanism of action, drug class) — Approved indications for use — Dosing regimens — Key safety warnings — Contraindications — PBS listing details (item numbers, restrictions, pricing) — Regulatory history beyond initial ARTG registration (PBAC assessments, AusPAR details)
To produce an accurate, properly cited Brand Dossier meeting the specified format and length requirements, I would need source documents containing: — Product information or clinical data sheets — PBAC submission documents or outcomes — AusPAR (Australian Public Assessment Report) if available — PBS listing details — Safety and efficacy information from clinical trials or regulatory assessments
Would you be able to provide additional source documents with this information?